News in brief: Lymphoma leader moves to The Alfred; Plastic particle exposure reflected in bloodstream; GLP-1 RAs may have antiplatelet effects

Tuesday, 19 Apr 2022


Lymphoma leader moves to The Alfred

Professor Constantine Tam

Professor Constantine Tam

Professor Con Tam has been appointed the inaugural Head of the Lymphoma Service at Alfred Health.

The appointment will spearhead the development of a program of excellence – expanding lymphoma research and providing access to new therapies for patients.

Professor Harshal Nandurkar, Director of Haematology at Alfred Health, said Professor Tam was highly regarded internationally in the area of lymphoma.

“Con has been the lead author on several innovative clinical trials that have given us much improved options for the treatment of lymphoproliferative conditions. We are excited to work with Con at Alfred Health and Monash University,” he said.

Among his research, Professor Tam has led studies on the second-generation BTK inhibitor zanabrutiniib, designed and conducted the first global study combining ibrutinib and venetoclax, and was principal investigator on the study of tisagenlecleucel in DLBCL.


Plastic particle exposure reflected in bloodstream

Micro- and nanoplastic particles from ingested or inhaled sources such as personal care products, dental polymers and nanomedicines have been detected in the human bloodstream.

A Dutch biomonitoring study used double shot pyrolysis-gas chromatography/ mass spectrometry (Py-GC/MS) to measure polymer mass concentrations in blood samples from 22 healthy volunteers.

The study found 77% of donors (n = 17) carried a quantifiable mass of plastic particles in their blood. Polyethylene terephthalate (PET) was the most widely encountered (in 50% of donors), followed by polymerised styrene (36%), polyethylene (23%) and poly(methyl methacrylate) in 5%.

“This indicates that at least some of the plastic particles humans come in contact with can be bioavailable and that the rate of elimination via e.g. the biliary tract, kidney or transfer to and deposition in organs is slower than the rate of absorption into the blood,” the study said.

The researchers said the duration of plastic particles in the bloodstream and the health effects are as yet unknown.

Read more in Environment International


GLP-1 RAs may have antiplatelet effects

GLP-1 receptor agonists such as liraglutide may have antiplatelet effects that account for their cardiovascular benefits, according to Victorian researchers.

A study of the antiplatelet effects of liraglutide in 16 patients with type 2 diabetes found that when taking an average dose of 1.8 mg/day  for 6 months, showed a significant, early and transient decrease in maximum slope of platelet aggregation in response to collagen, arachidonic acid and ADP.

The effect was seen within the first week and was seen with the lowest dose, the researchers from Monash University said.

The biological mechanisms responsible for the liraglutide-mediated attenuation of platelet aggregation were unknown but might be related to a direct effect on GLP-1 receptors on platelets or a non-GLP-1R-mediated nitrous oxide (NO)-generating mechanism previously suggested for the GLP-1R agonist exenatide, they said.

Read more in in the Journal of Diabetes and Its Complications

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2022 the limbic